Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2023 Earnings Call Transcript

Tasos Konidaris: Greg on the refinancing as you know our term loan B doesn’t come up for — that doesn’t become due in two years, right? So it’s May 2025. So there is plenty of runway, right? It’s kind of having said that I was the CFO in 2007, 2008 and 2009. So having lived through that you never know what happens to the capital markets. So this is why as a company we want to be constructive and that’s why we said we would like to extend to kind of refinance our term loan B sometime this year. So we’re in active conversations with the market. We have a number of kind of great investors in our current term loan B. Love to see many of them have expressed an interest to kind of continue in our refinancing efforts. So we’ll continue to try to be constructive with the market, but not at any cost and not at any terms. So our expectation is continue to focus in kind of getting it done before the end of the year. And if it goes beyond that so be it.

Greg Fraser: Thank you.

Operator: We have no further questions registered. I’ll turn the call back to Chirag for closing remarks.

Chirag Patel: Thank you very much. So just closing out just summarizing Amneal is a diversified differentiated and growing across all businesses. It’s a show-me study. We know that and we’ve been showing it. We’ll be showing more. That’s what we are doing. And we are laser-focused on execution driving higher EBITDA and deleveraging. And our future is very bright. And so we’re very excited. All 7,000 employees are extremely excited to make Amneal the American Champion and be the leading affordable medicine company for the United States. Thank you very much.

Chintu Patel: Thank you.

Operator: Thank you everyone for joining us today. This concludes our call and you may now disconnect your lines.